Singapore's life sciences sector, anchored by the Biopolis research hub and Tuas Biomedical Park, is one of the nation's fastest-growing industries with over 60 biomedical companies including GSK, Roche, and Amgen operating manufacturing and R&D facilities. A*STAR's Bioinformatics Institute and the Genome Institute of Singapore are at the forefront of AI-driven drug discovery and genomic research. The National Precision Medicine programme (Phase II) is building AI capabilities on population-scale genomic datasets, positioning Singapore as Asia's biomedical AI hub.
Life sciences companies face HSA's stringent regulatory requirements for AI-assisted drug development and clinical trial design, requiring extensive validation and clinical evidence. Singapore's small population limits the diversity and scale of clinical trial datasets available for AI model training, necessitating cross-border data partnerships that PDPA cross-border transfer rules govern. The high cost of wet-lab validation for AI-generated drug candidates means that computational predictions must meet rigorous accuracy thresholds before proceeding to Singapore-based synthesis and testing.
HSA regulates pharmaceutical products and medical devices, with AI-assisted drug discovery and manufacturing subject to GMP (Good Manufacturing Practice) compliance requirements. The Health Sciences Authority's Centre for Drug Administration evaluates AI-generated evidence in drug registration applications. A*STAR and the National Research Foundation (NRF) fund AI research in life sciences through the RIE2025 programme, with specific biomedical sciences funding allocated to AI applications.
We understand the unique regulatory, procurement, and cultural context of operating in Singapore
Singapore's data protection law requiring consent for personal data collection and use. AI systems handling personal data must comply with PDPA obligations including notification, access, and correction requirements.
Monetary Authority of Singapore guidelines for responsible AI use in financial services. Emphasizes explainability, fairness, and accountability in AI decision-making for banking and finance applications.
IMDA and PDPC framework providing guidance on responsible AI deployment across all sectors. Covers human oversight, explainability, repeatability, and safety considerations for AI systems.
Financial services data must remain in Singapore per MAS regulations. Public sector data governed by Government Instruction Manuals. No strict data localization for non-sensitive commercial data. Cloud providers commonly used: AWS Singapore, Google Cloud Singapore, Azure Singapore.
Enterprise procurement typically involves 3-month evaluation cycles with formal RFP process. Government procurement follows GeBIZ tender system with 2-4 week quotation periods. Decision-making concentrated at C-suite level. Budget approvals typically require board approval for >S$100K. Pilot programs (S$20-50K) can be approved by VPs/Directors.
SkillsFuture Enterprise Credit (SFEC) provides up to 90% funding for employee training, capped at S$10K per organization per year. Enterprise Development Grant (EDG) covers up to 50% of qualifying project costs including AI implementation. Productivity Solutions Grant (PSG) supports pre-scoped AI solutions with up to 50% funding.
Highly educated workforce with strong English proficiency. Low power distance enables direct communication with senior management. Results-oriented culture values efficiency and measurable outcomes. Fast adoption of technology but risk-averse in implementation. Prefer proof-of-concept before full deployment.
Explore articles and research about AI implementation in this sector and region
Article
A guide to prompt engineering courses for Singaporean companies in 2026. SkillsFuture subsidised workshops covering prompt patterns, structured output techniques, and governance.
Article
AI governance courses for Singaporean companies in 2026. SkillsFuture subsidised programmes covering PDPA compliance, IMDA Model AI Framework, MAS guidelines, and responsible AI.
Article
Singapore's Model AI Governance Framework has evolved through three editions — Traditional AI (2020), Generative AI (2024), and Agentic AI (2026). Together they form the most comprehensive voluntary AI governance framework in Asia.
Article
The Monetary Authority of Singapore (MAS) released AI Risk Management Guidelines in November 2025 for all financial institutions. Built on the FEAT principles, these guidelines establish comprehensive AI governance requirements for banks, insurers, and fintechs.
Our team has trained executives at globally-recognized brands
YOUR PATH FORWARD
Every AI transformation is different, but the journey follows a proven sequence. Start where you are. Scale when you're ready.
ASSESS · 2-3 days
Understand exactly where you stand and where the biggest opportunities are. We map your AI maturity across strategy, data, technology, and culture, then hand you a prioritized action plan.
Get your AI Maturity ScorecardChoose your path
TRAIN · 1 day minimum
Upskill your leadership and teams so AI adoption sticks. Hands-on programs tailored to your industry, with measurable proficiency gains.
Explore training programsPROVE · 30 days
Deploy a working AI solution on a real business problem and measure actual results. Low risk, high signal. The fastest way to build internal conviction.
Launch a pilotSCALE · 1-6 months
Roll out what works across the organization with governance, change management, and measurable ROI. We embed with your team so capability transfers, not just deliverables.
Design your rolloutITERATE & ACCELERATE · Ongoing
AI moves fast. Regular reassessment ensures you stay ahead, not behind. We help you iterate, optimize, and capture new opportunities as the technology landscape shifts.
Plan your next phaseThe programme, managed by PRECISE (Precision Health Research, Singapore), is sequencing 100,000 Singaporean genomes to build a multi-ethnic genomic database for AI-driven research. This dataset enables AI models to identify population-specific disease markers and drug response patterns across Singapore's Chinese, Malay, Indian, and other ethnic groups. Life sciences companies can access de-identified datasets through collaborative research agreements for AI drug discovery applications.
HSA accepts AI-generated evidence as part of drug registration submissions, provided it meets scientific rigour standards and is supported by appropriate clinical validation. The Therapeutic Products Guidance on AI/ML-based tools provides a framework for incorporating AI in drug development processes. HSA participates in international regulatory harmonisation through ICH guidelines, ensuring Singapore's approach to AI in drug development aligns with global standards.
Let's discuss how we can help you achieve your AI transformation goals.
